Impel Neuropharma Stock Fundamentals
Fundamental analysis of Impel Neuropharma allows traders to better anticipate movements in Impel Neuropharma's stock price by examining its financial health and performance throughout various phases of its business cycle.
Impel |
Impel Neuropharma Company Operating Margin Analysis
Impel Neuropharma's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Impel Neuropharma Operating Margin | (2.55) % |
Most of Impel Neuropharma's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Impel Neuropharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
CompetitionBased on the recorded statements, Impel Neuropharma has an Operating Margin of -2.5505%. This is 92.73% lower than that of the Biotechnology sector and 97.72% lower than that of the Health Care industry. The operating margin for all United States stocks is 53.71% lower than that of the firm.
Impel Neuropharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Impel Neuropharma's current stock value. Our valuation model uses many indicators to compare Impel Neuropharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Impel Neuropharma competition to find correlations between indicators driving Impel Neuropharma's intrinsic value. More Info.Impel Neuropharma is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Impel Neuropharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Impel Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Impel Neuropharma's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Impel Neuropharma could also be used in its relative valuation, which is a method of valuing Impel Neuropharma by comparing valuation metrics of similar companies.Impel Neuropharma is currently under evaluation in operating margin category among its peers.
Impel Fundamentals
| Return On Equity | -25.46 | |||
| Return On Asset | -0.62 | |||
| Operating Margin | (2.55) % | |||
| Current Valuation | 115.52 M | |||
| Shares Outstanding | 23.9 M | |||
| Shares Owned By Insiders | 0.52 % | |||
| Shares Owned By Institutions | 71.61 % | |||
| Number Of Shares Shorted | 851.5 K | |||
| Price To Book | 18.46 X | |||
| Price To Sales | 0.05 X | |||
| Revenue | 20.99 M | |||
| Gross Profit | 6.16 M | |||
| EBITDA | (68.96 M) | |||
| Net Income | (74.28 M) | |||
| Cash And Equivalents | 97.83 M | |||
| Cash Per Share | 4.12 X | |||
| Total Debt | 51.19 M | |||
| Current Ratio | 6.26 X | |||
| Book Value Per Share | (3.87) X | |||
| Cash Flow From Operations | (79.09 M) | |||
| Short Ratio | 0.36 X | |||
| Earnings Per Share | (3.12) X | |||
| Target Price | 40.0 | |||
| Number Of Employees | 160 | |||
| Beta | 1.17 | |||
| Market Capitalization | 5.76 M | |||
| Total Asset | 88.55 M | |||
| Retained Earnings | (321.11 M) | |||
| Working Capital | 57.65 M | |||
| Z Score | -6.56 | |||
| Net Asset | 88.55 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in Impel Stock
If you are still planning to invest in Impel Neuropharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Impel Neuropharma's history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |